Latest Headlines

31. BD Launches New Cell Analyzer Configurations To Bring Cutting-Edge Capabilities To Labs Of All Sizes 12/5/2025

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new configurations of cell analyzers featuring breakthrough spectral and real-time cell imaging technologies, enabling more labs in academia, pharma and biotech – across scales, needs and budgets – to advance discoveries in immunology, cancer immunotherapy and cell biology.

32. Natera Acquires Foresight Diagnostics 12/5/2025

    Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight.

33. Purity Scientific Launches Complimentary Technical Support Line To Help Laboratories Troubleshoot Analytical Instruments 12/3/2025

    Purity Scientific, together with its subsidiaries GenTech Scientific and Conquer Scientific, announced the launch of a complimentary technical support line to help laboratories resolve issues with chromatography, spectrometry, and other analytical instruments.

34. Acupath And Valar Labs Announce Strategic Partnership To Deliver Vesta, AI-Powered Diagnostic Tests For Non–Muscle Invasive Bladder Cancer 12/3/2025

    Acupath Laboratories, a leading provider of subspecialized anatomic pathology services, today announced a strategic partnership with Valar Labs to offer Vesta Bladder, Valar Labs’ AI-powered diagnostic test portfolio, to Acupath’s customers nationwide.

35. Liebherr Expands Scientific And Healthcare Portfolio With New Generation Of Undercounter Appliances 12/2/2025

    Liebherr USA, Co., Refrigerators and Freezers Division is proud to introduce its latest line of undercounter refrigerators and freezers, specially designed for the safe storage of temperature-sensitive substances, pharmaceutical products and flammable materials.

36. Perspectum And InHealth Announce National Diagnostics Partnership To Boost Oxford CDC Capacity And Widen Access To Advanced MRI Across The UK 12/2/2025

    Perspectum and InHealth have announced a new national diagnostics partnership that will significantly expand access to advanced MRI and increase capacity at the Oxford Community Diagnostic Centre (CDC).

37. Siemens Healthineers Advances Coronary Artery Disease Management With Syngo.CT Coronary Cockpit Software 12/2/2025

    At RSNA 2025, Siemens Healthineers announces Syngo.CT Coronary Cockpit¹, a new software solution within the Syngo.via² platform designed to support the management of coronary artery disease (CAD) for both dual-source and photon-counting CT scanners.

38. A Molecular 'Reset Button' For Reading The Brain Through A Blood Test 12/2/2025

    Tracking how genes switch on and off in the brain is essential for understanding many neurological diseases, yet the tools to monitor this activity are often invasive or unable to capture subtler changes over time.

39. Roche Receives FDA Clearance With CLIA Waiver And CE Mark For Its First Point-Of-Care Test For Diagnosing Bordetella Infections, Including Whooping Cough (Pertussis) 12/2/2025

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its first point-of-care test for the diagnosis of whooping cough (pertussis) and other Bordetella infections, has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) waiver, in addition to CE IVDR certification.

40. YD Bio Limited Expands OkaiDx™ Testing Portfolio To Pancreatic And Colorectal Cancer Detection Across The U.S. And Provides Clinical Research Update On Pancreatic Cancer Early Detection 12/2/2025

    YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today provided an update to its November 5, 2025 announcement regarding U.S. access to the OkaiDx™ platform for post‑treatment breast cancer monitoring, detailing the continued expansion of OkaiDx™ blood‑based testing platform to pancreatic and colorectal cancer detections while presenting new clinical advances in early pancreatic cancer detection.